Figures computed from official regulatory filings — .
Ownershipinsiders 5.73% · institutions 0%
In EUR · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for POXEL only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases. It also develops treatments for rare metabolic diseases and associated steatohepatitis to metabolic dysfunction. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial dysfunction; and Sumitomo Pharma for development and commercialization of Imeglimin. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.
Market information source · Oct 19, 2026
Open-market timeline · full history
4 buys— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| KUHN THOMAS | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 59 |
| AMF |
| KUHN THOMAS | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | AMF |
| KUHN THOMAS | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 75First in 12mo | AMF |
| KUHN THOMAS | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | AMF |
| KUHN THOMAS | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | AMF |
| Thomas Kuhn | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 55 | AMF |
| Thomas Kuhn | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 70First in 12mo | AMF |